TrialClinical rheumatology2018

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.

Désirée van der Heijde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.